Plexxikon’s unique discovery platform allows for the creation of novel, competitively differentiated drugs that have improved pharmacologic properties over many of today's available therapies.
The company has demonstrated the ability to move multiple programs from discovery to IND in just two years, significantly improving typical pharmaceutical development timelines at reduced costs. Additionally, the development team has executed successfully early clinical trials, including through clinical proof-of-concept.
Plexxikon is seeking collaborations with companies for a number of programs for which the company expects to file INDs during the next six to 12 months.
Current unpartnered programs include opportunities in:
CNS: Multiple Sclerosis Program Fact Sheet
Inflammation: Rheumatoid Arthritis Program Fact Sheet